1-2 of 2
Hiroaki Nagashima
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CDKN2A/B Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition

Ali M. Nasser, Lisa Melamed, Ethan A. Wetzel, Jenny Chia-Chen Chang, Hiroaki Nagashima, Yosuke Kitagawa, Logan Muzyka, Hiroaki Wakimoto, Daniel P. Cahill, Julie J. Miller
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2996–3005.
https://doi.org/10.1158/1078-0432.CCR-24-0562
Published: 15 July 2024
View article titled, <em>CDKN2A/B</em> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition
Open the PDF for <em>CDKN2A/B</em> Homozygous Deletion Sensitizes IDH-Mutant Glioma to CDK4/6 Inhibition in another window
Includes: Supplementary data
Journal Articles

Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair

Fumi Higuchi, Hiroaki Nagashima, Jianfang Ning, Mara V.A. Koerner, Hiroaki Wakimoto, Daniel P. Cahill
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (7): 1690–1699.
https://doi.org/10.1158/1078-0432.CCR-19-2000
Published: 01 April 2020
View article titled, Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Open the PDF for Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair in another window
Includes: Supplementary data